Erratum: Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer. (American Society for Biochemistry and Molecular Biology Inc. (2014) 289 (26417-26429) DOI: 10.1074/jbc.M114.553818)

Based on misinterpretation of the NMR spectra provided by our chemical vendor, the structure of VPC-14449 should be corrected. VPC-14449 (4-(4-(4,5-bromo-1H-imidazol-1-yl)thiazol-2-yl)morpholine) should be replaced with VPC-14449 (4-(4-(2,4-dibromo-1H-imidazol-1-yl)thiazol-2-yl)morpholine). In Fig. 1A, the graphical representation of VPC-14449 should be changed to the correct structure. Our industry partner synthesized the published VPC-14449 structure (4,5-bromo) and noticed that its NMR spectrum was different from that of our VPC-14449 stock synthesized by our chemical vendor. Upon synthesizing the correct structure (2,4-bromo), it was found that the NMR spectrum of the newly synthesized 2,4-bromo compound superimposed with the NMR spectrum of the compound supplied by our chemical vendor, establishing that the original compound used in this article was the 2,4-bromo version. In conclusion, our stock of VPC-14449 supplied by our chemical vendor and used in this article is (4-(4-(2,4-dibromo-1H-imidazol-1-yl)thiazol-2-yl)morpholine). This error does not affect the results or conclusions of this work, as we simply reported the incorrect structure of our compound.